Characterization & Causative Factors of Negative Dysphotopsia

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The present study is designed as an exploratory study, seeking to investigate the correlation of patient complaints to subjective or objective measurement methods. Better understanding of causative factors of negative dysphotopsia will improve detection and maybe prediction of this optical phenomenon.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01550939` - Time Study for Biometry Measurements With the Lenstar and IntraOcularLens (IOL) Master 500	Phase 4
	Completed	`NCT02138123` - Intraocular Lens-shell Technique in Phacoemulsification	N/A

NCT number	NCT04224129
Study type	Observational
Source	Vienna Institute for Research in Ocular Surgery
Contact	Oliver Findl, MD, Prof.
Phone	004319102157564
Email	office@viros.at
Status	Recruiting
Phase
Start date	January 2016
Completion date	May 2021

Characterization and Causative Factors of Negative Dysphotopsia — NDys

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms